12-Jun-2026
No headlines found.
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 27-May 7:00 AM ET)
MediWound to Report First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 8:00 AM ET)
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
Globe Newswire (Mon, 13-Apr 7:30 AM ET)
MediWound to Present New EscharEx Data at Leading Wound Care Conferences
Globe Newswire (Tue, 7-Apr 7:00 AM ET)
MediWound Reports BARDA Contract Award to Vericel for NexoBrid Valued at up to $197 Million
Globe Newswire (Thu, 2-Apr 3:26 PM ET)
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Mediwound Ltd. - trades on the NASDAQ stock market under the symbol MDWD.
As of June 12, 2026, MDWD stock price climbed to $14.22 with 46,836 million shares trading.
MDWD has a beta of 0.97, meaning it tends to be less sensitive to market movements. MDWD has a correlation of 0.09 to the broad based SPY ETF.
MDWD has a market cap of $182.52 million. This is considered a Micro Cap stock.
Last quarter Mediwound Ltd. - reported $1 million in Revenue and -$.23 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.43.
In the last 3 years, MDWD traded as high as $24.00 and as low as $7.10.
The top ETF exchange traded funds that MDWD belongs to (by Net Assets): IWM, IZRL, IWO, VTWO, IWC.
MDWD has underperformed the market in the last year with a return of -30.1%, while the SPY ETF gained +24.1%. In the last 3 month period, MDWD fell short of the market, returning -14.2%, while SPY returned +11.6%. However, in the most recent 2 weeks MDWD has outperformed the stock market by returning -0.8%, while SPY returned -1.9%.
MDWD support price is $13.65 and resistance is $14.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDWD shares will trade within this expected range on the day.